Home›Trial›NCT05853367
🔬NCT05853367Phase 1RECRUITING

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

Study Summary

The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors.

Conditions
Metastatic Solid TumorsAdvanced Solid Tumors
Interventions / Drugs
MK-0472PembrolizumabMK-1084
View on ClinicalTrials.gov ↗
Sponsor
MRK
Merck & Co
Oncology/Vaccines
F34/100
Study Details
Enrollment178 participants
Primary Completion—
Lead SponsorMerck Sharp & Dohme LLC
Data Retrieved2026-04-11 02:55:36.205815+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.